Glimepiride + Pioglitazone Tablets

Therapeutic Indication

Type 2 Diabetes Mellitus

Improves glycemic control

Combination therapy for insulin resistance and beta-cell dysfunction

+91 85919 78885

Glimepiride + Pioglitazone

Tablet

This fixed-dose combination of Glimepiride (a sulfonylurea) and Pioglitazone (a thiazolidinedione) is used to improve glycemic control in patients with type 2 diabetes mellitus.

Speciality	Diabetology \| Endocrinology \| Internal Medicine
Tags	Antidiabetic \| Sulfonylurea \| Thiazolidinedione \| Combination therapy
Strength	Glimepiride 2 mg Pioglitazone 15 mg
Packing Size	10 Tablets

Check all Tablets Range

Click to know More

Mechanism

Glimepiride stimulates pancreatic beta cells to release insulin, while Pioglitazone improves insulin sensitivity in peripheral tissues by activating PPAR-γ receptors.

Pharmacokinetics

Absorption: Well absorbed orally.
Metabolism: Glimepiride metabolized in liver (CYP2C9); Pioglitazone extensively metabolized hepatically.
Excretion: Primarily via urine and feces.
Half-life: Glimepiride ~5–8 hours; Pioglitazone ~16–24 hours.

Side Effects

Hypoglycemia
Weight gain
Edema
Headache
Rare: hepatotoxicity, heart failure risk

Contraindication

Hypersensitivity to sulfonylureas or thiazolidinediones
Type 1 Diabetes Mellitus
Severe hepatic impairment
Heart failure (NYHA Class III/IV)

Interaction

Other antidiabetic drugs (risk of hypoglycemia)
CYP2C9 inhibitors/inducers (altered Glimepiride metabolism)
Insulin (increased risk of edema)

Warning and Precautions

Monitor blood glucose regularly
Assess liver function before and during therapy
Use with caution in patients with cardiovascular disease
Not recommended during pregnancy unless essential